Piramal Pharma Future Growth
Future criteria checks 4/6
Piramal Pharma is forecast to grow earnings and revenue by 67.1% and 11.8% per annum respectively. EPS is expected to grow by 68.1% per annum. Return on equity is forecast to be 11.4% in 3 years.
Key information
67.1%
Earnings growth rate
68.1%
EPS growth rate
Pharmaceuticals earnings growth | 17.4% |
Revenue growth rate | 11.8% |
Future return on equity | 11.4% |
Analyst coverage | Good |
Last updated | 23 Jul 2024 |
Recent future growth updates
Recent updates
Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
3/31/2027 | 116,840 | 9,523 | N/A | 15,891 | 2 |
3/31/2026 | 104,620 | 5,459 | 8,044 | 14,490 | 6 |
3/31/2025 | 92,079 | 2,346 | 3,660 | 11,155 | 6 |
3/31/2024 | 81,712 | 178 | 2,925 | 10,045 | N/A |
12/31/2023 | 78,435 | -333 | N/A | N/A | N/A |
9/30/2023 | 76,009 | -1,336 | -992 | 8,655 | N/A |
6/30/2023 | 74,096 | -1,760 | N/A | N/A | N/A |
3/31/2023 | 70,816 | -1,865 | -4,809 | 4,839 | N/A |
12/31/2022 | 72,228 | -325 | -6,634 | 3,382 | N/A |
9/30/2022 | 69,535 | 2,210 | N/A | N/A | N/A |
6/30/2022 | 67,532 | 2,626 | N/A | N/A | N/A |
3/31/2022 | 67,341 | 3,760 | -1,231 | 7,664 | N/A |
3/31/2021 | 58,868 | 7,708 | -43 | 5,516 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPLPHARMA's forecast earnings growth (67.1% per year) is above the savings rate (6.7%).
Earnings vs Market: PPLPHARMA's earnings (67.1% per year) are forecast to grow faster than the Indian market (16% per year).
High Growth Earnings: PPLPHARMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PPLPHARMA's revenue (11.8% per year) is forecast to grow faster than the Indian market (9.5% per year).
High Growth Revenue: PPLPHARMA's revenue (11.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPLPHARMA's Return on Equity is forecast to be low in 3 years time (11.4%).